Womb Starvation: Tiny Hearts, Ticking Clock

Newborn infants resting in hospital cribs in a nursery

Doctors can now predict which unborn babies are running out of time in the womb — and the window to act is measured in days, not weeks.

At a Glance

Fetal growth restriction starves babies of oxygen and nutrients before birth, raising the risk of stillbirth, brain damage, and lifelong health problems.
A landmark trial called TRUFFLE found that using a specific blood flow measurement in the fetal heart vessel called the ductus venosus to decide when to deliver saved more babies from brain damage than older monitoring methods.
Over 80% of severely growth-restricted babies in the TRUFFLE trial survived to age two with no detectable brain damage, despite being born very early.
There is still no drug to fix the root cause — a failing placenta — so doctors can only watch closely and choose the safest moment to deliver.

When the Placenta Fails, the Clock Starts Ticking

Fetal growth restriction, or FGR, happens when a baby stops growing at a normal rate inside the womb. The cause is almost always a placenta that cannot deliver enough oxygen and nutrients. The baby’s body responds by rationing blood flow to the brain, heart, and adrenal glands, while other organs suffer. Left undetected, this slow starvation can end in stillbirth or permanent neurological damage. Catching it early — and knowing exactly when to deliver — is the entire game.

The challenge is that small size alone does not tell the full story. Some babies are simply small because their parents are small. Doctors now use individualized growth charts that factor in parental height, weight, and ethnicity to separate constitutionally small fetuses from truly growth-restricted ones. That distinction matters enormously. Misclassifying a healthy small baby as growth-restricted leads to unnecessary early delivery, with all the risks that brings. Missing a genuinely sick baby leads to tragedy.

The TRUFFLE Trial Changed How Doctors Decide When to Deliver

Before the TRUFFLE trial, doctors relied mainly on cardiotocography — a continuous fetal heart rate monitor — to decide when a growth-restricted baby was in enough danger to deliver early. TRUFFLE tested whether adding Doppler measurements of the ductus venosus, a small vessel that carries blood directly to the fetal heart, could improve outcomes. The trial enrolled severely growth-restricted babies between 26 and 32 weeks of pregnancy, a period when every extra day in the womb matters enormously for brain development.

The results were striking. Babies whose delivery was triggered by late changes in ductus venosus blood flow had a 95% survival rate without neurodevelopmental problems at two years of age. ^[5] More than 80% of all babies in the trial, even the most severe cases, survived to age two without detectable neurological impairment. ^[3] That is a remarkable outcome for babies born so dangerously early. The TRUFFLE data gave doctors a more precise tool — one that could buy extra days in the womb without letting the baby deteriorate past the point of recovery.

For Babies Near Term, the Strategy Shifts

A separate trial called DIGITAT studied growth-restricted babies closer to full term. It found no meaningful difference in newborn death rates between delivering early and waiting with close monitoring. The practical takeaway from DIGITAT is that delivery around 38 weeks, combined with careful surveillance, prevents stillbirth without increasing neonatal death. Waiting past that point adds risk without adding benefit. Earlier delivery before 38 weeks, however, raised neonatal intensive care unit admissions without reducing mortality — a reminder that aggressive early delivery carries its own costs.

The Honest Limits of What Medicine Can Do Right Now

Here is the frustrating truth that every specialist in this field acknowledges: there is no drug that fixes a failing placenta. No treatment reverses FGR once it starts. Doctors can correct underlying maternal conditions like high blood pressure or diabetes, but the placental damage itself remains beyond reach. Abnormal Doppler readings double the risk of bad outcomes independent of fetal size alone, ^[6] yet all doctors can do with that information is watch more closely and choose the delivery moment carefully. Management is entirely about surveillance and timing.

About one-third of early-onset FGR cases develop maternal preeclampsia, which can force delivery based on the mother’s condition regardless of where the fetus stands in the monitoring protocol. ^[3] That reality limits how precisely doctors can optimize timing for the baby. And delivery before 30 weeks, while sometimes unavoidable, independently raises the risk of neurodevelopmental problems — creating a narrow, high-stakes window where the decision to deliver carries serious consequences either way.

What Comes Next Could Change Everything

The TRUFFLE 2 trial is studying growth-restricted babies between 32 and 37 weeks — a large group that current protocols handle inconsistently. ^[9] Results are expected to clarify whether ductus venosus Doppler should guide delivery decisions in this late preterm group the same way it does for earlier cases. Separately, researchers at Cambridge and the University of Colorado are investigating molecular pathways, including the role of fetal glucagon as a regulator of placental function, that could one day lead to actual treatments rather than just better timing. ^[1] The surveillance era may eventually give way to an intervention era. For now, the best weapon doctors have is knowing exactly when to act.